WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a ...

The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and ...

A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and the latest evidence of interest in buying ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...

Mural Oncology has agreed to be acquired by biotechnology royalty aggregator XOMA Royalty in a deal worth up to $38.8 million. Mural on Wednesday said XOMA will pay an initial $2.035 a share in cash, ...

Clinical-stage California-based biotech Mural Oncology and XOMA Royalty Corporation , a biotechnology royalty aggregator have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly ...

Mural Oncology plc (NASDAQ: MURA), a clinical-stage immuno-oncology company, and XOMA Royalty Corporation (NASDAQ: XOMA), a biotechnology royalty aggregator, announced today they have entered into a ...

Detailed price information for Xoma Corp 8.625% (XOMAP-Q) from The Globe and Mail including charting and trades.

XOMA Royalty Corporation (XOMA) on Wednesday reported second-quarter net income of $9.2 million. On a per-share basis, the ...

Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or ...

Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently announ ...

Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...